Kimberly Manhard
Kimberly Manhard's purchase track record
Kimberly Manhard has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/28/2024 | INBX | $140K | +12.0% | -9.7% | +6.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Transaction History
| INBX | ▼ Sell | Open Market | 500 | $53K | 9/15/2026 | View on chart |
| INBX | ▼ Sell | Open Market | 500 | $55K | 9/14/2026 | View on chart |
| INBX | ▼ Sell | Open Market | 500 | $56K | 9/11/2026 | View on chart |
| INBX | ▼ Sell | Open Market | 500 | $58K | 9/9/2026 | View on chart |
| INBX | ▼ Sell | Open Market | 500 | $58K | 9/8/2026 | View on chart |
| INBX | ▲ Buy | Open Market | 10,000 | $140K | 8/28/2024 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 4/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 4/13/2023 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 1,417 | $4K | 4/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 1/13/2023 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 1/13/2023 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $6K | 1/13/2023 | View on chart |
| HRTX | ▼ Sell | Other | 1,655 | $5K | 10/31/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 10/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 10/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $8K | 10/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $6K | 7/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 7/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 7/13/2022 | View on chart |
| HRTX | ▼ Sell | Open Market | 1,504 | $7K | 5/3/2022 | View on chart |
| HRTX | ▼ Sell | Other | 1,504 | $6K | 4/29/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 4/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 4/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $12K | 4/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 1/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 4,564 | — | 1/13/2022 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 2,012 | $17K | 1/13/2022 | View on chart |
| HRTX | ▲ Buy | Option Exercise | 1,250 | — | 10/13/2021 | View on chart |
| HRTX | ▼ Sell | Tax Withholding | 433 | $5K | 10/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Inhibrx to Present at Upcoming Scientific Conferences
Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.
Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.